A conference of the MIT Laboratory for Financial Engineering
In collaboration with the National Cancer Institute
and with the participation of the American Cancer Society
and the American Association for Cancer Research
Dedicated to the Memory of Thomas A. Tombrello
October 26-28, 2014
Cambridge, MA
CanceRx 2014 is an invitation-only conference hosted by MIT focusing exclusively on new approaches to financing biomedical innovation in oncology and other areas. The conference will bring together representatives from key stakeholder communities including academia and medical research centers, community hospitals, the biopharma industry, health plans, NIH/NCI, the FDA, patient advocacy groups, investment banks, hedge funds, credit rating agencies, biotech VCs, and institutional and retail investors.
The conference will be organized as a series of panel discussions—with substantial audience participation—devoted to addressing the funding challenges facing academia and the biopharma industry, including:
- Updates on fundraising initiatives and their business models since CanceRX 2013
- Recent scientific and clinical breakthroughs and potential business implications
- Financial modeling techniques for managing biopharma assets and liabilities
- Innovations in intellectual property rights management and licensing structures
- The changing role of government, patient advocacy groups, and philanthropy
In addition, an optional executive education program, “Basic Financial Analysis for Life Sciences Professionals,” will be offered from 1:00 to 5:00pm on Sunday October 26, followed by the welcome dinner at 6:00pm. Space for this educational program is limited to 100 participants on a first-come-first-served basis.[This text is here for extra space][This text is here for extra space]
Conference Steering Committee: David B. Agus, University of Southern California; Margaret Anderson, FasterCures; Chris Austin, National Center for Advancing Translational Sciences; Edward Benz, Dana-Farber Cancer Institute; Douglas A. Dachille, First Principles Capital Management; Margaret Foti, American Association for Cancer Research; Jacob Goldfield; Peter Hancock, AIG; H. Robert Horvitz, MIT; Robert Langer, MIT; Pablo Legorreta, Royalty Pharma; Judy Lewent; J. Leonard Lichtenfeld, American Cancer Society; Frank McCormick, University of California, San Francisco; Robert C. Merton, MIT Sloan School of Management; Lita Nelsen, MIT Technology Licensing Office; Larry Norton, Memorial Sloan-Kettering Cancer Center; Marty Tenenbaum, Cancer Commons; Thomas Tombrello, Caltech; Jake Xia, Harvard Management Company.
View their bios